Plerixafor, identified by its Chemical Abstracts Service (CAS) number 155148-31-5, stands as a pivotal pharmaceutical intermediate in the landscape of modern medical treatments. This unique chemical compound, characterized by its molecular formula C28H62Cl8N8 and a molecular weight of 830.500, appears as a distinctive primrose yellow substance with a minimum purity of 99%. Its primary significance lies in its critical role as an immunostimulant, specifically designed for the mobilization of hematopoietic stem cells (HSCs).

Hematopoietic stem cell transplantation (HCT) is a life-saving procedure for patients battling certain blood cancers, most notably non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). In autologous HCT, a patient's own stem cells are collected, processed, and then reinfused after high-dose chemotherapy or radiation. The challenge often lies in efficiently collecting a sufficient number of these vital stem cells from the bone marrow. This is where Plerixafor (CAS 155148-31-5) plays a transformative role. It functions by disrupting the interaction between CXCR4, a protein on the surface of stem cells, and SDF-1α in the bone marrow, effectively releasing these stem cells into the peripheral bloodstream where they can be readily collected through a process called apheresis.

Clinical studies have consistently demonstrated the superior efficacy of Plerixafor in combination with growth factors like filgrastim. This synergistic approach significantly reduces mobilization failures and achieves higher success rates in collecting the target number of stem cells. Patients often require fewer apheresis procedures, leading to a more efficient and less burdensome collection process. By making stem cells more accessible, Plerixafor facilitates successful transplantation, offering a renewed hope for patients undergoing intensive cancer treatment. The ability to enhance stem cell harvest is a cornerstone for successful autologous HCT, contributing to faster engraftment and recovery of blood cell counts post-transplant.

While Plerixafor offers immense therapeutic benefits, its administration requires careful medical oversight. It is typically given as a subcutaneous injection prior to apheresis sessions, often in conjunction with filgrastim. Healthcare professionals monitor patients closely for potential side effects, which can include common reactions such as diarrhea, nausea, vomiting, fatigue, injection site reactions, headache, and dizziness. More serious, though less common, effects can involve changes in blood cell counts (like increases in white blood cells or decreases in platelets), potential spleen enlargement, or allergic reactions. It is important to note that Plerixafor is not intended for patients with leukemia, as it may inadvertently mobilize leukemic cells.

NINGBO INNO PHARMCHEM CO.,LTD. stands as a reliable manufacturer and supplier of high-quality Plerixafor (CAS 155148-31-5). Our commitment to stringent quality control ensures that our pharmaceutical intermediate meets the rigorous demands of the global market. For those looking to buy or purchase this essential compound, we offer competitive price options and flexible bulk package solutions. We are dedicated to providing the foundational chemical components that empower life-saving therapies worldwide, supporting advancements in cancer treatment and patient care.